Randomized trial · people
Semaglutide 7.2 mg: 18.7% weight loss at 72 weeks in STEP UP
Checked against the paper Randomized trialPublished by PepVault
The takeaway
In this trial, the 7.2 mg dose brought 3.1% more weight loss than 2.4 mg over 72 weeks, along with more gut side effects and more frequent skin-sensation side effects.
- Kind
- Randomized trial
- Studied in
- People
- Number studied
- 1407
- Published
- 2025
- Journal
- Lancet Diabetes Endocrinol
What they tested
The team tested whether a higher weekly dose of semaglutide, 7.2 mg, leads to more weight loss than placebo and the 2.4 mg dose in adults with obesity, and how safe it is.
How the study was done
A randomized, double-blind trial in 1407 adults with a BMI of 30 kg/m2 or more and no diabetes, at 95 sites in 11 countries. For 72 weeks they got weekly injections of semaglutide 7.2 mg, semaglutide 2.4 mg, or placebo (a dummy shot), all alongside a lifestyle program.

Model. Individual results vary.
What they found
Body weight fell by 18.7% in the 7.2 mg arm, 15.6% in the 2.4 mg arm and 3.9% in the placebo arm, putting 7.2 mg ahead of 2.4 mg by 3.1% and ahead of placebo by 14.8%. People on 7.2 mg were more likely than those on 2.4 mg to lose 20% or more of their weight (odds ratio 1.8) and 25% or more (odds ratio 2.4), and waist size shrank by 11.7 cm more than with placebo. Gut side effects hit 70.8% on 7.2 mg, 61.2% on 2.4 mg and 42.8% on placebo, and dysesthesia (odd or unpleasant skin sensations) hit 22.9%, 6.0% and 0.5%. Serious adverse events occurred in 6.8%, 10.9% and 5.5%, and the authors judged the 7.2 mg dose's risk-benefit balance favorable.
What it doesn’t show
The trial lasted 72 weeks and left out people with diabetes. Its 2.4 mg and placebo arms were much smaller than the 7.2 mg arm, and 73.7% of participants were female. It was funded by Novo Nordisk.
The paper
Wharton et al. Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial. Lancet Diabetes Endocrinol. 2025.
The compound
More studies on Semaglutide
- CagriSema: 18.4% weight loss vs 11.9% on semaglutide in REDEFINE 5Randomized trial · people · 2026
- Semaglutide (oral): smaller HbA1c drop than orforglipron in ACHIEVE-3Randomized trial · people · 2026
- Semaglutide (oral) did not slow early Alzheimer's in evoke trialsRandomized trial · people · 2026
- Semaglutide: 36% vs 0% hit glucose and weight goal in type 1 diabetesRandomized trial · people · 2025
- Semaglutide 25 mg pill: 13.6% weight loss at 64 weeks in OASIS 4Randomized trial · people · 2025
- Semaglutide: MASH resolved in 62.9% vs 34.3% on placebo at 72 weeksRandomized trial · people · 2025
- Every study on Semaglutide
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.